Videos

Expert explains how delaying BCOP certification too long after a PGY2 residency can cause a “if you don’t use it, you’ll lose it” problem.

Students from the Daniel K. Inouye College of Pharmacy at the University of Hawaii discuss the importance of culturally competent care in Hawaii.

Dr Teena Chopra shares her approach to monitoring patients with C difficile infection (CDI).

Drs Tom Lodise and Bincy Abraham provide an overview of fecal microbiota transplantation and long-term safety of FMT use.

The most important thing you must do is listen to the patient, understand their concerns, and by doing that, you will gain their trust to be able to treat them appropriately.

Migraines are multifactorial and patient-specific, causing accessible care and treatments to be limited and ignored.

Experts review treatment options for first, second and recurring episodes of Clostridioides difficile infection.

A gastroenterologist reviews the long-term impact of dysbiosis and Clostridioides difficile infection.

Pharmacy Times spoke with Carina Dolan, PharmD, Editor in Chief of the Pharmacy Market Outlook, about the highlights and the big picture moving forward for hospitals and health systems.

Hawaii has a distinct culture, and the students said that has led them to have unique perspectives on culturally competent care.

About 1 in 8 women in the United States will develop breast cancer in their lifetime. Overall mortality for breast cancer has decreased over the years with the addition of complex treatment, such as PARP inhibitors. The webcast discusses this class of medications and see how they fit into the treatment paradigm for breast cancer.

Dr. Tom Lodise provides an overview of gut microbiota and the consequences of dysbiosis.

Dr. Abraham discusses importance of differential diagnosis of C. difficile infection (CDI) in patients with IBD and how both IBD and CDI should be managed.

The COVID-19 pandemic accelerated many changes in the pharmacy field, but maintaining that momentum and working together will be essential for the future growth of pharmacy.

The FDA initially approved baloxavir marboxil in October 2018 for the treatment of acute, uncomplicated influenza.

Doug Long and Scott Biggs of IQVIA discussed how data from Australia can help predict the strength of the upcoming flu season.

Bill Schimmel, CEO and executive director of the Pharmacy Technician Certification Board (PTCB), discusses why pharmacy technicians are leaving the profession and why they are staying.

Students from the Daniel K. Inouye College of Pharmacy discuss their experience at the University of Hawaii.

Patients who had previously hit their out-of-pocket maximums could see a significant change.

Bill Schimmel, CEO and executive director of the Pharmacy Technician Certification Board (PTCB), discusses how pharmacists and pharmacy technicians can advocate for the certification of pharmacy technicians.

Scott Biggs and Doug Long of IQVIA discussed where the pharmacy industry stands now and what they predict for the future.

Although it may not have immediate significant impacts for many patients, the Inflation Reduction Act could open the door for future changes.

Rina Shah, PharmD, discussed the growing role for pharmacists in encouraging holistic health and wellness for patients.

Bill Schimmel, CEO and executive director of the Pharmacy Technician Certification Board (PTCB), discusses how pharmacy technicians can face burnout and advocate for themselves.

A gastroenterologist, Dr. Bincy Abraham, provides an overview of C. difficile infection (CDI) in patients with inflammatory bowel disease (IBD).

Drs. Lodise and Feuerstadt discuss educational opportunities to combat and reduce C. difficile infection (CDI).

Paul Forsberg, PharmD, BCOP, MHA, director of Pharmacy Services at Minnesota Oncology discusses how pharmacists can remain on top of shifts in the nature of biosimilar payer benefit design.

Desmond Hunt, PhD, senior principal scientist at US Pharmacopeia (USP), discusses the standards and resources that USP has recently published or is looking at now on the subject of pharmacy in transit.

Although innovation in the pharmacy space is continuing nearly 3 years into the COVID-19 pandemic, provider status and reimbursement are both necessary to continue this innovation in the future.

In addition to garnering more public awareness in recent years, expert Michael Zimmerman said supply chain disruptions have “hyper-evolved” during the COVID-19 pandemic.